Blood
Articles in this Issue
Rapid ADAMTS13 activity assays for thrombotic thrombocytopenic purpura: a systematic review and meta-analysis
Abstract Thrombotic thrombocytopenic purpura (TTP) is a rare, potentially fatal thrombotic microangiopathy caused by severe ADAMTS13 (a disintegrin and metalloproteinase with thrombo...
Iron overload impacts TCR γδ cell immunity
Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma
Abstract G protein-coupled receptor, class C, group 5, member D (GPRC5D) has emerged as a novel target for chimeric antigen receptor (CAR) T-cell therapy, demonstrating promising eff...
Reshaping the TME to enhance checkpoint blockade in ENKTL
Redefining risk stratification in pLCH
When increased bone marrow blasts may not mean malignancy
The neutrophil antigen 3a/b polymorphism in <i>SLC44A2</i> unexpectedly encodes the Csa/Csb red cell antigens
Abstract The Csa blood group antigen was identified &gt;50 years ago, but its genetic basis has yet to be elucidated. All our recent genomic investigation has failed to resolve t...
Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma
Abstract Idecabtagene vicleucel (ide-cel) was the first US Food and Drug Administration–approved chimeric antigen receptor T-cell (CAR-T) therapy for multiple myeloma (MM). However,...
Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma
Abstract This study aimed to assess the efficacy and safety of combining cemiplimab, an anti–programmed cell death protein 1 (PD-1) antibody, with isatuximab, an anti-CD38 antibody,...
Real-world data provide a CARbon copy for ide-cel
Silence of the myeloma clones: GPRC5D epigenetic regulation
<i>BRAF</i> V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH
Abstract Langerhans cell histiocytosis (LCH) is a myeloid neoplastic disorder driven by mitogen-activated protein kinase (MAPK) activation in hematopoietic cells. Historically, LCH h...
ANKRD26-related thrombocytopenia 2 with a baseline increase in blasts: implications for clinical surveillance
Abstract We report on 8 patients with ankyrin repeat domain 26 (ANKRD26)–related thrombocytopenia 2 (ANKRD26-RT) with elevated bone marrow myeloblasts and dysmegakaryopoiesis, withou...
A rare phenotype of peripheral T-cell lymphoma, NOS: coexpression of CD15, CD20, and T follicular helper markers in a <i>DUSP22</i>alt case
Unveiling the truth: different names, same antigen
Beware the zombie enzyme
TTP: a disorder for all physicians
Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia
Abstract Targeted therapy with covalent Bruton tyrosine kinase inhibitors (cBTKis) and/or the B-cell lymphoma 2 inhibitor (BCL-2i) venetoclax is now well established in the first-lin...
Blunted CD40-responsive enhancer activation in <i>CREBBP</i>-mutant lymphomas can be restored by enforced CD4 T-cell engagement
Abstract The CREBBP lysine acetyltransferase (KAT) is frequently mutated in follicular lymphoma and diffuse large B-cell lymphoma and has been studied using gene knockout in murine a...
Iron overload in HFE-related hemochromatosis severely impairs Vδ2+ γδ T-cell homeostasis
Abstract HFE-related hemochromatosis induces systemic iron overload. Although extensive studies indicate a pivotal role for iron homeostasis in αβ T-cell immunity, its effect on γδ T...